Should you buy Progyny stock? (NASDAQ:PGNY). Let's see how it does in our automated value investing analysis system.
Advantages | Disadvantages | Neutral |
---|---|---|
|
|
|
PGNY Price (Progyny stock price per share) |
$30.57 | |
PE Ratio versus Sector | 66% higher than other Healthcare stocks | |
PE Ratio versus Industry | 0% lower than other Health Information Services stocks |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 5,581,017 shares shorted. With 74,417,963 shares available for purchase and an average trading volume over the past 10 trading days of 1,268,160, it would take at least 4.401 days for all of the short holders to cover their shorts.
Based on our analysis, we believe that you should not buy Progyny right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.
Does Progyny have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles
What are The Dow, S&P 500, and NASDAQ Indexes?
What Happened to the Stock Market Today?
What are Broker Fees (and how to pay less)?
Why Do Companies Pay Dividends?
What is Self-Directed Investing?